Thu. 22 Feb 2024, 7:19am ET
Benzinga
Earnings, News
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(2.67) per share. This is a 1.91 percent decrease over losses of $(2.62) per share from the same period last year. The company reported $20.76 million in sales this quarter. This is a 33.25 percent decrease over sales of $31.10 million the same period last year.